Open-label Phase 3b Study to Investigate the Safety of Ross River Virus (RRV) Vaccine From 6 to 12 Months After the Third Vaccination in Healthy Adults (Follow up to Precursor Study 880801) [EXTENSION OF 700191470]

Trial Profile

Open-label Phase 3b Study to Investigate the Safety of Ross River Virus (RRV) Vaccine From 6 to 12 Months After the Third Vaccination in Healthy Adults (Follow up to Precursor Study 880801) [EXTENSION OF 700191470]

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Ross River virus vaccine (Primary) ; Aluminium hydroxide
  • Indications Ross River virus infections
  • Focus Adverse reactions; Registrational
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 05 Apr 2013 New trial record
    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top